1Q23 Performance Overview

CLINICS & DIAGNOSTICS BUSINESS OPERATING PERFORMANCE OVERVIEW REVENUE DEVELOPMENT² +3.0% EBITDA¹ DEVELOPMENT GEORGIA CAPITAL ☐ CLINICS & DIAGNOSTICS KEY DRIVERS Our clinics and diagnostics business's decreased revenue and EBITDA were due to the significantly reduced number of COVID cases in the country and the suspension of COVID contracts from mid-March 2022 by the Government. The business is showing a rebounding trend in revenues from non-covid services in 1Q23 as evidenced by: о О a 38.5% y-o-y increase in the revenues from non-COVID, regular ambulatory services at our polyclinics; a 103.2% y-o-y increase in revenues from non-COVID services at our community clinics; a 14.5% y-o-y increase revenues from regular lab tests in 1Q23, at our diagnostics business. GEL MILLION ■Clinics 28 -21.7% -38.9% 21 21 8 4 20 17 4 5 65 15 1Q21 1Q22 1Q23 Diagnostics - Total KEY OPERATING HIGHLIGHTS Clinics Number of admissions ('000) Number of registered patients ('000) 638.6 595 Diagnostics Average revenue per non-covid test (GEL) Number of non-covid tests performed ('000) 6.1 603 -45.4% 3 3 4 1Q21 1Q22 1Q23 Clinics Diagnostics 1Q22 VS. ■ 1Q23 Change y-o-y 510.1 617 -20.1% +3.7% 6.9 +13.4% 608 +0.9% Georgia Capital PLC | General note: All figures are presented excluding Medical Centre University Clinic (HTMC). 1. Excluding IFRS 16. 2. Total revenue excludes eliminations between the clinics & diagnostics business lines. 72

View entire presentation